Document is current
Any future updates will be listed below
-
Authors
,
Fouarge, Eve https://orcid.org/0000-0002-3929-7599
Monseur, Arnaud
Boulanger, Bruno
Annoussamy, Mélanie
Seferian, Andreea M.
De Lucia, Silvana
Lilien, Charlotte
Thielemans, Leen
Paradis, Khazal
Cowling, Belinda S.
Freitag, Chris
Carlin, Bradley P.
Servais, Laurent
-
Funding
Funding for this research was provided by:
Dynacure
Valerion Therapeutics
Genethon
- License Information
-
More Information
Article History
Received: 23 June 2020
Accepted: 22 December 2020
First Online: 6 January 2021
Ethics approval and consent to participate
: The NHS in which these data were acquired was approved by all institutional ERBs of hospitals where the studies were conducted; all patients or caregivers for minors gave ERB-approved informed consent.
: Not applicable.
: LS is member of the SAB of Dynacure and has conducted consultancy for Audentes, two companies involved in CNM therapies. CL has conducted consultancy for Audentes. CF, BSC, and LT are employed by Dynacure. AM and BB are employees of Pharmalex, an independent vendor of Dynacure. KP is a paid consultant to Dynacure and other rare disease companies.
